Barton v. The Procter & Gamble Company

Summary

The United States District Court for the Southern District of California considers Defendant The Procter & Gamble Company’s motion to dismiss a putative class action concerning alleged lead in Tampax Pearl and Tampax Radiant tampons. The court finds that Plaintiffs plausibly pleaded California UCL, FAL, and CLRA claims based on alleged misleading packaging representations and testing allegations, and it denies the motion to dismiss.

Holdings

1. At the pleading stage, plaintiffs were not required to test the specific tampon units they purchased, allege that those units came from the same lot as the tested units, or plead that each specific purchase contained lead when they alleged uniform products and testing across all relevant sizes.
2. The testing allegations satisfied Rule 9(b) because plaintiffs identified the testing methodology, timing, laboratory qualifications, and the tested product sizes with sufficient detail.
3. Plaintiffs plausibly alleged that the packaging representations, read in context, could mislead reasonable consumers into believing that the tampons were free of potentially harmful substances, including lead.
4. Even representations that are true and discrete may plausibly be misleading when considered in the context of the product's overall packaging and marketing.
5. The FTC Green Guides did not require dismissal because plaintiffs challenged health-and-safety marketing representations rather than environmental marketing claims.
6. Plaintiffs failed to plausibly state a UCL claim under the unfair prong because their allegations merely recited the applicable tests and were conclusory.
7. Plaintiffs could proceed under the UCL unlawful prong based on their adequately pleaded CLRA affirmative-misrepresentation claim.
8. Plaintiffs adequately pleaded that legal remedies were inadequate and could pursue equitable relief under the UCL, FAL, and CLRA at the pleading stage.

Questions Presented

1. Whether the Second Amended Complaint plausibly pleaded UCL, FAL, and CLRA claims based on affirmative misrepresentations in tampon labeling.
2. Whether the testing allegations satisfied Federal Rule of Civil Procedure 9(b) despite not testing the specific units purchased by plaintiffs or identifying the tested lots.
3. Whether plaintiffs plausibly alleged that the product representations were material and likely to mislead reasonable consumers based on alleged lead levels and potential health risks.
4. Whether the FTC Green Guides governed the alleged health-and-safety representations or required dismissal of the consumer-protection claims.
5. Whether plaintiffs stated a UCL claim under the unfair and unlawful prongs.
6. Whether plaintiffs adequately pleaded the inadequacy of legal remedies to pursue equitable relief under the UCL, FAL, and CLRA.

Disposition

other